0001231919-25-000321.txt : 20251016 0001231919-25-000321.hdr.sgml : 20251016 20251015173232 ACCESSION NUMBER: 0001231919-25-000321 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20251016 DATE AS OF CHANGE: 20251015 EFFECTIVENESS DATE: 20251016 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pheast Therapeutics, Inc. CENTRAL INDEX KEY: 0001943737 ORGANIZATION NAME: EIN: 871616936 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-560984 FILM NUMBER: 251395810 BUSINESS ADDRESS: STREET 1: 200 CARDINAL WAY, STE 300 CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-374-2223 MAIL ADDRESS: STREET 1: 200 CARDINAL WAY, STE 300 CITY: REDWOOD CITY STATE: CA ZIP: 94063 D 1 primary_doc.xml X0708 D LIVE 0001943737 Pheast Therapeutics, Inc. 200 CARDINAL WAY, STE 300 REDWOOD CITY CA CALIFORNIA 94063 650-374-2223 DELAWARE None None Corporation true 2020 Roy Maute c/o Pheast Therapeutics, Inc. 200 Cardinal Way, Suite 300 Redwood City CA CALIFORNIA 94063 Executive Officer Director Amira Barkal c/o Pheast Therapeutics, Inc. 200 Cardinal Way, Suite 300 Redwood City CA CALIFORNIA 94063 Director Steven Gillis c/o Pheast Therapeutics, Inc. 200 Cardinal Way, Suite 300 Redwood City CA CALIFORNIA 94063 Director Jacob Vogelstein c/o Pheast Therapeutics, Inc. 200 Cardinal Way, Suite 300 Redwood City CA CALIFORNIA 94063 Director Thomas Marty c/o Pheast Therapeutics, Inc. 200 Cardinal Way, Suite 300 Redwood City CA CALIFORNIA 94063 Executive Officer Raphael Rousseau c/o Pheast Therapeutics, Inc. 200 Cardinal Way, Suite 300 Redwood City CA CALIFORNIA 94063 Executive Officer Irving Weissman c/o Pheast Therapeutics, Inc. 200 Cardinal Way, Suite 300 Redwood City CA CALIFORNIA 94063 Director Other Technology Decline to Disclose 06b false 2025-10-07 false true true true false 0 39999993 24588083 15411910 false 7 0 0 0 false Pheast Therapeutics, Inc. /s/ Roy Maute Roy Maute CEO 2025-10-15